sar425899 glp-1 glucagon dual agonist sanofi Receptor occupancy of glucagon-like peptide 1/glucagon receptor in individuals with type 2 diabetes Gut hormone-based pharmacology: novel formulations

Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic poly-peptide (GIP, previously known as gastric inhibitory polypeptide) are key incretin

Survodutide also reduced waist circumference, an indicator of metabolic health.

Learn how weight loss drug coverage is changing for Medicare GLP-1 prescriptions in 2026 and how Absolute Best Insurance can help review options.

DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006

While most of the recent fanfare has been related to their ro...